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Human cytomegalovirus (CMV) is a common but
difficult to treat infection of immunocompromised
patients. MSL-109 is a human monoclonal IgG iso-
lated from a CMV seropositive individual that recog-
nizes the viral glycoprotein H (gH) surface antigen
complexes that mediate entry. Although MSL-109
blocks CMV infection in vitro, it lacked sufficient effi-
cacy in human trials, and CMV isolated from treated
patients suggested the evolution of MSL-109 resis-
tance. To understand how CMV escapes MSL-109,
we characterized a MSL-109-resistant CMV strain.
Our results elucidate a nongenetic escape mecha-
nism in which the antibody is selectively taken up
by infected cells and incorporated into assembling
virions in a dose-dependent manner. The resistant
virus then utilizes the Fc domain of the incorporated
antibody to infect naive nonimmune cells. This resis-
tance mechanism may explain the clinical failure of
MSL-109, illustrate a general mechanism of viral anti-
body escape, and inform antiviral vaccine and thera-
peutic development.
INTRODUCTION
Human cytomegalovirus (CMV) infects between 60% and 80%
of the adult population worldwide (Ho, 1990). Infection is usually
asymptomatic but results in a lifelong latent infection. Immuno-
compromised populations such as chemically immunosup-
pressed transplant patients, immune-naive neonates, and AIDS
patients commonly exhibit significant morbidity and mortality
as a result of CMV infection. The current therapy for CMV
disease is treatment with either ganciclovir or valganciclovir,
which are associated with significant toxicity and not approved
for use in pregnant women. As an alternative, CMV antibodies
have been used in the successful treatment of CMV-induced
disease. CMV hyperimmunoglobulin has demonstrated efficacy
in certain solid organ transplant recipients (Snydman, 1990), and
amore recent study found that pooled human IgG products from
CMV-positive individuals were effective at protecting infantsCell Host & Mfrom CMV disease when born to women with a primary infection
(Nigro et al., 2005). These findings suggest that antibody therapy
may prove to be an effective and safe alternative/addition to the
current forms of CMV therapy.
CMV entry is reliant upon the stepwise coordination of multiple
virus-encoded envelope proteins. Following the initial attach-
ment of the virus to the cell through interactions between the
virus gM/gN complex and heparan sulfate proteoglycans
(HSPGs) (Kari et al., 1994), the virus induces envelope fusion
with cellular membranes through a combination of glycoprotein
B (gB) and gH/gL complexes. The latter of these exists in two
forms; gH/gL/gO is required for replication in fibroblast cell
types, while gH/gL/UL128/UL130/UL131a is required for virus
entry into epithelial, endothelial, and dendritic cells but is typi-
cally mutated to eliminate function when the virus is passaged
in fibroblast cells (Hahn et al., 2004). In fibroblasts, CMV entry
occurs by fusion at the plasma membrane and is not dependent
on the lowering of pH in endocytic compartments (Compton
et al., 1992). In addition, there are also data supporting alterna-
tive routes of entry depending on the virus strain and cell type
tested (Patrone et al., 2007; Ryckman et al., 2006; Wang et al.,
2007), demonstrating that CMV entry is a complicated process
which may involve multiple entry routes depending on the
circumstances of infection.
MSL-109 is a human monoclonal IgG isolated from the spleen
of a CMV seropositive individual. It recognizes gH surface
antigen complexes and in vitro blocks the infection of fibroblasts
by laboratory and clinical strains of CMV (Nokta et al., 1994).
MSL-109 was tested as an adjuvant treatment for AIDS patients
with CMV-induced retinitis, but development was halted during
phase 2/3 clinical trials when data showed that MSL-109 lacked
sufficient efficacy (Jabs et al., 2002). There are a number of
possible reasons for its failure to work in vivo. For example,
in silico analysis of the amino acid sequence of MSL-109 re-
vealed potential deamidation sites within complementarity
determining region (CDR) regions that may have affected its
physiochemical properties in vivo. Also, the patient population
in which it was tested was possibly suboptimal for measuring
its efficacy, as the eye is an immune privileged site. Although
both of these explanations are possible, a previous study of
CMV isolated from MSL-109-treated patients suggested the
virus had generated resistance to the antibody (Li et al., 1995).
The mechanism of resistance was found not to require the muta-
tion of the target protein, suggesting that CMV has alternativeicrobe 10, 197–209, September 15, 2011 ª2011 Elsevier Inc. 197
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izing antibodies. To further understand this mechanism, we
generated a MSL-109-resistant strain of CMV. Our findings
confirm that antibody resistance can occur without any genetic
changes and is generated rapidly by the selective incorporation
of the antibody into the virion in a dose-dependent manner. This
unusual mechanism of resistance provides an important insight
into how CMV may escape the immune systems antibody
response, and offers valuable information for the successful
design of future monoclonal antibody therapies for CMV.
RESULTS
Characterization of MSL-109 Binding
MSL-109 blocks entry of several CMV clinical isolates into
multiple cell types with IC50 values ranging between 0.03 and
1.02 mg/ml (see Table S1 available with this article online). The
reported target of MSL-109 is the virus envelope glycoprotein,
gH (Lakeman et al., 1991). To confirm that MSL-109 binds to
gH-containing complexes, we tested antibody binding to cells
expressing gH in combination with glycoprotein L (gL). The
gH/gL or gB complexes were displayed on the surface of adult
retinal pigment epithelial-19 (ARPE-19) cells by adenovirus
transduction, and FACS analysis was used to detect antibody
binding. We also tested two other naturally occurring human
antibodies, 13H11 and ITC88, which target gH and gB, respec-
tively. Both MSL-109 and 13H11 bound to gH/gL-expressing
cells, but not to mock-transduced cells or gB-expressing cells
(Figure 1A). ITC88 bound to gB-expressing cells, but not to
mock-transduced cells or gH/gL-expressing cells. In addition,
we also tested the ability of MSL-109 to immunoprecipitate
various forms of gH/gL-containing complexes from neonatal-
normal human dermal fibroblasts (NN-NHDFs). MSL-109 was
found to immunoprecipitate gH, but not an irrelevant cellular
transmembrane receptor, DDR1, indicating that it specifically
binds to the known gH-containing complexes (Figure 1B).
UL131a was also immunoprecipitated from cells expressing
the gH/gL/UL128/UL130/UL131a complex. These data confirm
that MSL-109 recognizes gH/gL complexes on cells.
To test the ability of MSL-109 to immunoprecipitate gH from
virions, purified VR1814 was complexed with either MSL-109,
13H11, or ITC88. As expected, ITC88 immunoprecipitated gB
from virion lysates (Figure 1C). 13H11 immunoprecipitated gH
but not gB, but in contrast MSL-109 was unable to immunopre-
cipitate either gB or gH from virions. Therefore, MSL-109 is
capable of recognizing gH when it is expressed in cells but is
not capable of recognizing gH when it is mixed with cell-free
virions. To confirm this, we performed ELISA assays using either
soluble gH/gL/UL128/UL130/UL131a complex, soluble gB, or
purified VR1814 virions. ITC88 was bound to soluble gB and
VR1814 virions, while 13H11 bound to soluble gH/gL/UL128/
UL130/UL131a complexes and VR1814 virions (Figures 1D–
1G). The pooled CMV hyperimmunoglobulin Cytotect bound to
soluble gB and gH/gL/UL128/UL130/UL131a in addition to intact
virions. MSL-109 bound soluble gH/gL/UL128/UL130/UL131a,
confirming that it is capable of recognizing gH in this complex,
but was unable to bind intact VR1814 virions. Additionally,
experiments mixing free VR1814 virions with antibody in solution
also demonstrated a lack of binding (Figure S1). These data198 Cell Host & Microbe 10, 197–209, September 15, 2011 ª2011 Elshow that MSL-109 binds to gH/gL complexes via an epitope
that is only exposed following interaction with the cell and blocks
a step subsequent to the initial attachment of the virus to the cell.
Generation of MSL-109-Resistant Virus
To generateMSL-109-resistant virus, we subjected VR1814 (moi
0.5) to multiple rounds of infection in the presence of antibody.
Initially multiple concentrations of antibody were tested to
generate resistance and 4.4 mg/ml was found to be the lowest
dose that generated a shift in the IC50 value of over 100-fold
(data not shown). This was the concentration of antibody used
to generate the initial preparation of resistant virus, and subse-
quent rounds were generated in 6.6 mg/ml. NN-NHDF cells
were infected with VR1814 in the presence of the antibody,
and the flask was monitored for cytopathic effects (CPEs).
When all the cells demonstrated CPE, the virus was harvested
and used for the next round of infection. A total of three rounds
were carried out before the virus was assessed for its suscepti-
bility to MSL-109, 13H11, ITC88, or an additional anti-gH anti-
body, 3G16. MSL-109 completely neutralized parental VR1814
with IC50 values in the 1 mg/ml range. Virus grown in the presence
of MSL-109 approached an IC50 value100-fold higher and was
not able to neutralize more than 50% of the input virus (Fig-
ure 2A). These data indicate that the virus had escaped antibody
neutralization, and we subsequently called this virus VR1814-
MSL109R. The escape virus was still susceptible to the anti-gB
antibody ITC88, with an IC50 value of 0.24 mg/ml, and to two anti-
bodies that recognize different epitopes on gH (13H11 and
3G16) with IC50 values of 1.24 mg/ml and 6.11 mg/ml, respectively
(Figure 2A). The ability of both gH-targeting antibodies and ITC88
to block VR1814-MSL109R infection indicates that the virus still
expresses and uses gH and gB to enter cells.
Plaque-purified MSL-109-resistant clones were generated
and tested for antibody susceptibility. All of the clones were
resistant toMSL-109 with IC50 values over 100 mg/ml (Figure 2B).
To examine if there was a loss of fitness associated with resis-
tance, plaque-purified VR1814-MSL109R was used to generate
growth curves and compared to parental VR1814. VR1814-
MSL109R grew at a similar rate to wild-type VR1814, although
at day 16 there was a slight reduction in VR1814-MSL109R as
compared to VR1814 (Figure 2C). These data indicate that there
is little to no fitness cost to the generation of resistance.
CMV Resistance to MSL-109 Is Not Dependent
on a Genetic Change and Is Reversible
To identify themechanismof resistance, all of the CMVglycopro-
teins that are known to be required for virus entry (gH, gL, gO,
UL128, UL130, UL131a, gB, gM, and gN) were sequenced.
VR1814-MSL109R sequences were aligned with those of both
the parental VR1814 virus and the published VR1814 sequence.
There were no coding mutations identified in any of the genes
with known roles in virus entry, including both gH and gL. To
establish if there were genetic mutations anywhere in the 234
kbp genome that tracked with resistance, we sequenced the
full genome of eight plaque-purified viruses in addition to the
parental VR1814 virus. We obtained complete coverage for all
nine genomes (Table S2), and the sequencing reads were map-
ped onto the published VR1814 sequence. We analyzed all of
the known and predicted HCMV open reading frames (ORFs)sevier Inc.
Figure 1. MSL-109 Binds to HCMV gH/gL in a Cell-Associated Form
(A) Adenoviruses were used to express either gH/gL or gB in ARPE-19 cells. Cell surface glycoprotein expression was detected using MSL-109, ITC88, or 13H11
antibodies.
(B) NN-NHDF cells were transduced with adenoviruses to express different gH containing complexes. Forty-eight hours p.i., lysates were harvested and
immunoprecipitated using MSL-109. Immunoblotting was used to detect the presence of gH, UL131a, or DDR1.
(C) gH and gB were immunoprecipitated from an equivalent number of purified infectious virions using MSL-109, 13H11, or ITC88. The presence of gH or gB was
detected by immunoblotting.
(D–G) MSL-109, 13H11, and ITC88 were bound to immobilized BSA (D), soluble gH/gL/128/130/131 complex (E), soluble gB (F), or VR1814 virions (G). Binding
was detected using an anti-human HRP conjugated antibody (also see Figure S1 and Table S1). Error bars represent ±SD.
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Figure 2. VR1814-MSL109R Has Escaped MSL-109
(A) VR1814 or VR1814-MSL109R was incubated with 10-fold dilutions of antibody for 1 hr prior to the infection of NN-NHDF cells. Twenty-four hours p.i., cells
were stained for IE1/2 protein. The IC50 value was calculated for each antibody using the percentage of IE1/2-positive cells compared to the untreated control;
see also Table S1.
(B) Plaque-purified VR1814-MSL109R clones were tested for their susceptibility to MSL-109 as described in (A).
(C) NN-NHDF cells were washed three times in serum-freemedia and infected with either VR1814 or VR1814-MSL109R at anmoi of 0.05. VR1814-MSL109Rwas
infected and maintained in the presence of 6.6 mg/ml of MSL-109. At 0, 4, 8, 12, and 16 days p.i. virus was harvested. Plaque assay was used to establish the
number of infectious particles. Error bars represent ±SD.
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occurred. A high frequency of mutations occurred in three
ORFs, RL13, UL119, and UL131a (Figure 3A). Both RL13 and200 Cell Host & Microbe 10, 197–209, September 15, 2011 ª2011 ElUL131a frequently undergo mutations when the virus is continu-
ally passaged in fibroblasts (Dargan et al., 2010), so it is unsur-
prising that these genes show an accumulation of mutations.sevier Inc.
Figure 3. MSL-109 Escape Is Not Due to a Genetic Change
(A and B) The genomes of VR1814 and eight plaque-purified VR1814R-MSL109R clones were sequenced; ORFs RL13, UL131a, and UL119 accumulated
mutations in the resistance clones (A); see also Table S2. The percentage of reads containing each of these mutations for each clone is given (B).
(C) VR1814-, VR1814-MSL109R-, and VR1814-ITC88R-resistant viruses were grown in NN-NHDF cells in the absence of antibody. Susceptibility to MSL-109 or
ITC88 was tested by incubating virus with antibody for 1 hr before infection. The percent of IE1/2-expressing cells was determined and the IC50 was calculated.
(D–F) NN-NHDF cells were infected with VR1814 or VR1814-MSL109R for 3 days. Cells were then either stained for IE1/2 (D) or harvested for DNA (E) or RNA (F).
Quantitative real-time PCR was used to determine the DNA copy number or relative gene expression of virus glycoproteins.
(G) Equivalent numbers of infectious particles were separated using SDS-PAGE electrophoresis and then immunoblotted for the presence of virus glycoproteins.
Band intensity was determined using the ChemiDoc XRS and Quantity One software (Bio-Rad) (see also Table S2). Error bars represent ±SD.
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undergoes mutation during passage in fibroblasts. It is a
single-pass transmembrane receptor present in virions which
binds to human IgG antibodies by the Fc domain, and it has
been speculated that this is may be a mechanism by which the
virus evades detection by immune cells (Sprague et al., 2008).
Despite a high frequency of mutations occurring in these three
ORFs, the percentage of individual reads containing the muta-
tions varied considerably in the plaque-purified clones (Fig-
ure 3B), indicating that each clone was a heterogeneous popula-
tion for these mutations. As these clones were plaque purified
and maintained in the presence of the antibody, they should all
be homogenous for the mutation if it is responsible for resis-
tance. In addition, the parental VR1814 reads also demonstratedCell Host & Mthat there was a small population of virus that contained muta-
tions in RL13 and UL131a. Together the sequencing data indi-
cate that a simple genetic change is not responsible for antibody
resistance in VR1814-MSL109R.
To support this conclusion, we examined the reversibility of
the resistance phenotype by passaging VR1814-MSL109R in
the absence of the antibody and testing each passage of virus
for susceptibility to MSL-109. VR1814-ITC88R, which is resis-
tant to neutralization by the anti-gB antibody ITC88, was tested
in parallel. This virus contains a single nucleotide polymorphism
(SNP) in the binding site of the antibody. The IC50 value for MSL-
109 and VR1814-MSL109R was 4.48 mg/ml after just one pas-
sage, and the virus remained susceptible to the antibody for
the second and third passages with IC50 values of 2.59 mg/mlicrobe 10, 197–209, September 15, 2011 ª2011 Elsevier Inc. 201
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ITC88R remained resistant to ITC88 even when grown in the
absence of the antibody. To confirm that RL13, UL131a, and
UL119 are not responsible for MSL-109 resistance, we
sequenced the reverted VR1814-MSL109R virus and found
that the mutations in RL13, UL131a, and UL119 (Figure 3A) re-
mained in the reverted virus (data not shown). The rapid rever-
sion of the resistance phenotype argues against a permanent
genetic change being responsible for the resistance phenotype.
VR1814-MSL109R Expresses and Contains
Wild-Type gH
To address alternative mechanisms of resistance, we tested
VR1814-MSL109R for gH expression using qRT-PCR on RNA
harvested from VR1814-MSL109R- or VR1814-infected NN-
NHDF cells at 3 days postinfection (p.i.). The cells were infected
at anmoi of 0.5, and to ensure that the equivalent number of cells
were infected, we fixed and stained some of the cells for IE1/2
(Figure 3D). We also used qRT-PCR to confirm an equivalent
number of DNA genomes in the infected cells (Figure 3E). The
qRT-PCR data demonstrated that there was little difference in
the gene expression levels of IE1/2, gH, gL, UL128, UL130,
UL131a, gB, or gO (Figure 3F). These data indicate that resis-
tance was not due to an alteration in the expression of gH or
any of the other proteins currently known to interact with gH.
To test if reduced gH abundance in virions could account for
MSL-109 resistance, we compared protein levels of purified
resistant virus. To ensure that an equal number of virus particles
were compared, the number of infectious particles was quanti-
fied using immunoflorescence staining for infected cells, and
data were coupled with equivalent protein concentrations.
Equivalent amounts of virus were pelleted through a sorbitol
cushion, and the pellet was resuspended in lysis buffer and
SDS-PAGE electrophoresis used to separate the proteins.
Immunoblots confirmed that gH, gL, UL130, UL131a, and gB
were present in the VR1814-MSL109R virions to similar levels
as compared to wild-type VR1814 (Figure 3G). There was 62%
less UL128 present in VR1814-MSL109R as compared to wild-
type VR1814, but as MSL-109 can still block the entry of labora-
tory strains of CMV that do not have UL128 at all (Nokta et al.,
1994), it is unlikely that this is the cause of resistance. Together
with the data showing that other gH-targeting antibodies still
neutralize VR1814-MSL109R infection (Figure 2), these data
demonstrate that there is no loss of wild-type gH in VR1814-
MSL109R.
MSL-109 Resistance Is Dose Dependent and Involves
the Incorporation of the Antibody into
Assembling Virions
Since our data indicate that a genetic change is not responsible
for resistance, studies were performed to establish the relation-
ship between antibody concentration and resistance. We in-
fected NN-NHDF cells with VR1814 and p.i. added various
concentrations ofMSL-109. The cells were left for 9 days to allow
for virus production. The supernatant and intracellular virus was
harvested from each sample and tested for susceptibility to
MSL-109. Surprisingly, virus harvested from within the cell was
susceptible to MSL-109 regardless of the antibody concentra-
tion present in the culture media (Figure 4A), while virus obtained202 Cell Host & Microbe 10, 197–209, September 15, 2011 ª2011 Elfrom the supernatant had become resistant to MSL-109 in
a dose-dependent manner. These data indicate a close relation-
ship between the concentration of antibody and the generation
of resistance.
As there is a close relationship between antibody concentra-
tion and the generation of resistance, we tested wild-type or
resistant virions for the direct presence of the antibody.
VR1814-MSL109R was grown in the presence of increasing
doses of MSL-109 and compared to VR1814 grown in the
absence of any antibody, and the ITC88-resistant virus
(VR1814-ITC88R) was grown in the presence of 24 mg/ml of
ITC88. Purified virions were normalized to equivalent number
of infectious particles using both immunoflorescence of infected
cells and protein concentration determination as described
previously. Equivalent amounts of infectious virions were then
pelleted and resuspended in lysis buffer. The heavy chain of
human IgG was detected in VR1814-MSL109R virion lysates in
a dose-dependent manner, but not in VR1814 or VR1814-
ITC88R virions (Figure 4B). In addition, protein A/G immunopre-
cipitation of the human IgG from VR1814-MSL109R revealed
that it was bound to gH (Figure 4C). These data suggest that
the mechanism of antibody resistance is reliant upon the incor-
poration of the antibody by the virion in a dose-dependent
manner.
MSL-109 Is Selectively Taken Up into Infected Cells
andColocalizeswith gH in an Intracellular Compartment
Our data demonstrate that MSL-109 only binds gH when it is
associated with the cell. Therefore, in order for MSL-109 to
become incorporated into the virion it must bind to gH while it
is in its cell-associated form. Previous data have shown that
human IgG is taken up into CMV-infected cells (Keller et al.,
1976), likely due to virally encoded Fc receptors. To test this
with MSL-109, NN-NHDF cells were infected with VR1814
followed by the addition of cell culture media containing
6.6 mg/ml of MSL-109. The cells were then washed and fixed
3 days p.i. To detect the presence of MSL-109, cells were
stained with an anti-human AF488-conjugated antibody and co-
localized with an anti-gH mouse antibody. There was clear
uptake of MSL-109 into cells staining positive for gH, but there
was no detectable uptake into cells that showed no staining
(Figure 4D). There was also a strong colocalization between
MSL-109 and gH, indicating that the two proteins reach the
same intracellular compartment. This process, however, was
not limited to MSL-109 uptake, as ITC88 was also taken up
into infected cells and colocalized in the same compartment as
gH. These data confirm that there is a virus-induced mechanism
for the uptake of human IgG into cells that allows for the interac-
tion of MSL-109 with gH during the assembly and maturation of
the virion.
Bound MSL-109 Disrupts gH/gL/UL128/UL130/UL131a
Function
To investigate the fitness cost of virion-bound MSL-109, we
tested the function of the gH/gL/UL128/UL130/UL131a com-
plex. This complex is required for entry into epithelial, endothe-
lial, macrophage, and monocyte cell lines but is not required
for entry into fibroblasts (Ryckman et al., 2006). To test its func-
tion, we first tried to infect NN-NHDF cells, ARPE-19 cells,sevier Inc.
Figure 4. MSL-109 Is Incorporated into Resistant Virions in a Dose-Dependent Manner
(A) NN-NHDF cells were infected with VR1814, and 24 hr p.i. cells were treatedwith increasing concentrations ofMSL-109. Nine days p.i. virus was harvested and
tested for MSL-109 susceptibility as described above. Error bars represent ±SD.
(B) Equivalent numbers of infectious purified particles were subjected to SDS-PAGE electrophoresis, and the presence of human IgG or gBwas detected using an
anti-human HRP-conjugated secondary.
(C) Human IgG was immunoprecipitated from virus lysates and blotted for the presence of gH or pp65.
(D) NN-NHDF cells were infected with VR1814 and incubated with 6.6 mg/ml of either MSL-109 or ITC88 for 3 days before being fixed and stained. gH (red) was
detected using an anti-gH mouse antibody. MSL-109 or ITC88 were detected using an anti-human AF488-conjugated secondary antibody.
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foreskin fibroblasts (HFFs) with wild-type VR1814, VR1814-
MSL109R, or VR1814-ITC88R. VR1814 and VR1814-ITC88R
infected all four cell types (Figure 5A). VR1814-MSL109R was
only able to infect NN-NHDF and HFF cells, indicating that the
virus is defective for entry into nonfibroblast cell types. This is
seen in CMV strains that are deficient for gH/gL/UL128/UL130/
UL131a function.
Laboratory-adapted strains of CMV, such as AD169, lack the
gH/gL/UL128/UL130/UL131a complex and are unable to infect
nonfibroblast cell types. The block to infection in these cells is
thought to be at the stage of virus fusion and can be overcome
by the addition of PEG, which induces fusion of the virus
membrane with the plasma membrane. To test if the block to
VR1814-MSL109R infection of ARPE-19 cells is at the stage
of virus fusion, increasing amounts of VR1814, AD169, or
VR1814-MSL109R were added to ARPE-19 cells, and the cells
were then treated with PEG as previously described (RyckmanCell Host & Met al., 2006). Twenty-four hours after p.i., the number of IE1/2-
positive cells was determined as an indication that a productive
virus entry event had occurred. Treatment with PEG resulted in
an increase of IE1/2-positive cells for both VR1814-MSL109R
and AD169 (Figure 5B), suggesting that like AD169, VR1814-
MSL109R lacks a functional gH/gL/UL128/UL130/UL131a
complex.
Since the resistance phenotype is reversible, we tested
whether the defect in tropism was reversible. ARPE-19 cells
infected with VR1814-MSL109R, which had been grown in
the absence of antibody and was now susceptible to MSL-
109, were monitored for CPE for 21 days. The reverted virus
was capable of growing in ARPE-19 cells, and CPE rapidly
spread throughout the cell culture at a similar rate to the
parental VR1814 (Figure 5C), suggesting that although the
incorporation of MSL-109 causes a defect in gH/gL/UL128/
UL130/UL131a function, it can be reversed by removal of the
antibody.icrobe 10, 197–209, September 15, 2011 ª2011 Elsevier Inc. 203
Figure 5. VR1814-MSL109R Has an Altered Cellular Tropism
(A) NN-NHDF, HUVEC, HFF, and ARPE-19 cells were infected with increasing amounts of VR1814, VR1814-MSL109R, or VR1814-ITC88R. Twenty-four hours p.i.
the cells were stained for IE.
(B) VR1814, AD169, and VR1814-MSL109R were allowed to bind to ARPE-19 cells for 1 hr before the addition of PEG. Twenty-four hours p.i. the cells were
stained for IE1/2 protein.
(C) The reverted virus was used to infect ARPE-19 cells, and infection was monitored for 15 days p.i. Error bars represent ±SD.
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Endocytosis and Requires the Fc Domain of MSL-109
Since MSL-109 is attached to the virion but not able to block
entry of VR1814-MSL109R, we tested for any differences in
the mechanism of entry. We first compared the entry kinetics
of VR1814-MSL109R with those of parental VR1814. The resis-
tant virus entered cells at a slower rate than parental VR1814
(Figure 6A). At 3 hr p.i., over 50% of parental VR1814 was resis-
tant to low pH neutralization, while only about 30% of VR1814-
MSL109R was resistant. These data indicate a slower rate of
entry for VR1814-MSL109R.
CMV enters fibroblasts by direct fusion of the virus envelope
with the plasma membrane at neutral pH (Compton et al.,
1992). To test if VR1814-MSL109R entry still occurs at a neutral
pH, the acidification of endosomal and lysosomal compartments
was prevented by treating NN-NHDF cells with nontoxic concen-
trations of either ammonium chloride or chloroquine. The cells
were then infected with either parental VR1814 or VR1814-
MSL109R. VR1814 was resistant to both ammonium chloride
(Figure 6B) and chloroquine (Figure 6C) treatment. In contrast,
VR1814-MSL109R was susceptible to treatment with both204 Cell Host & Microbe 10, 197–209, September 15, 2011 ª2011 Elammonium chloride and chloroquine (Figures 6B and 6C). These
data confirm that VR1814-MSL109R enters cells using an alter-
native mechanism that requires low pH conditions.
To test for the involvement of clathrin-dependent endocytosis
or lipid raft-mediated endocytosis, including caveolae-mediated
endocytosis, cells were treated with either chlorpromazine or
nystatin, respectively. Cells were pretreated with nontoxic
concentrations of compound for 1 hr prior to infection with either
VR1814 or VR1814-MSL109R. As expected, VR1814 infection
was unaffected by the presence of either chlorpromazine or
nystatin (Figures 6D and 6E). In contrast, VR1814-MSL109R ex-
hibited a dose-dependent decrease in infection in the presence
of chlorpromazine (Figure 6D). VR1814-MSL109R was unaf-
fected by treatment with nystatin (Figure 6E). These data suggest
that the early stages of VR1814-MSL109R require clathrin-
dependent endocytosis.
To determine if the antibody itself was playing a role in
VR1814-MSL109R entry, we first tested the ability of an anti-
human IgG antibody to block VR1814-MSL109R entry. Fibro-
blasts were infected with either VR1814 or VR1814-MSL109R
that had been incubated with either MSL-109 or an anti-humansevier Inc.
Figure 6. VR1814-MSL109R Entry Is Ph Dependent and Reliant upon MSL-109 Fc Domain Availability
(A) VR1814 and VR1814-MSL-109R were allowed to bind to NN-NHDF cells for 45 min at 4C before being shifted to 37C. At various time points cells were
treated with low pH citrate buffer. Twenty-four hours p.i. cells were stained for IE1/2.
(B–E) Cells were treated with compound for 1 hr prior to infection. Infected cells were detected by IE1/2 staining.
(F) VR1814 or VR1814-MSL109R was treated for 1 hr with either a goat anti-human IgG antibody or MSL-109 before infecting NN-NHDF cells.
(G) NN-NHDF cells were treated with human IgG for 1 hr at 4C. Infection was allowed to occur at 37C for 2 hr before cells were treated with low pH citrate buffer.
(H) VR1814 and VR1814-MSL109R were incubated with protein A for 1 hr prior to the infection (see also Figure S2). Error bars represent ±SD.
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value of 0.59 mg/ml but was completely unaffected by pretreat-
ment with the anti-human IgG antibody (Figure 6F). The converseCell Host & Mwas true for VR1814-MSL109R, which was resistant to MSL-109
but was blocked by the anti-human IgG antibody with an IC50
value of 7.38 mg/ml. These data suggest that the Fc domain oficrobe 10, 197–209, September 15, 2011 ª2011 Elsevier Inc. 205
Figure 7. Model of MSL-109 Resistance
CMV infection (A) of cells triggers the uptake of MSL-109 (B). MSL-109 colocalizes with gH in an intracellular compartment, which allows for the attachment and
incorporation of MSL-109 into the virion (C). New virions are released with MSL-109 attached (D) and infect naive cells using the Fc domain of MSL-109 (E). The
infection process requires a pH-dependent step (F). New virions generated from cells in the absence of antibody do not contain the antibody and are now
susceptible to MSL-109 (G) (see also Figure S3 and Table S3).
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To confirm this, we tested whether protein A was capable of
blocking VR1814-MSL109R infection. NN-NHDF cells were in-
fected with either VR1814 or VR1814-MSL109R which had
been preincubated with protein A. Protein A treatment inhibited
VR1814-MSL109, but not VR1814, in a dose-dependent manner
(Figure 6G). Since both anti-human IgG and protein A were
capable of inhibiting resistant virus by binding to MSL109 in
the virion, we tested whether saturating Fc binding sites on cells
would also inhibit VR1814-MSL109R infection. Cells were incu-
bated with irrelevant human IgG at 4C before adding virus at
37C. Irrelevant human IgG inhibited the entry of VR1814-
MSL109R but had no effect on parental VR1814 (Figure 6H).
These data confirm a role for the Fc domain of MSL-109 in the
infection of NN-NHDF cells by VR1814-MSL109R.
DISCUSSION
MSL-109 is a naturally occurring human antibody which in vitro is
capable of blocking CMV infection of multiple cell types by tar-
geting gH glycoprotein complexes, but was unsuccessful as
a therapy for CMV disease. In this study MSL-109-resistant
CMV was generated to establish whether virus resistance could
account for its inefficacy in vivo. Here we demonstrate a mecha-
nism of CMV escape from a neutralizing antibody. The virus
generated rapid resistance by the dose-dependent attachment
of the antibody to gH complexes within CMV-infected cells,
and the resulting resistant virus demonstrated an alteration in
the mechanism of virus entry (Figure 7). The resistance mecha-
nism is not reliant upon the generation of a genetic mutation206 Cell Host & Microbe 10, 197–209, September 15, 2011 ª2011 Eland is reversible upon removal of the antibody. The virus was
able to replicate in fibroblast cells to similar levels as wild-type
CMV, but there was a fitness cost to the generation of resistance,
as the virus was unable to infect nonfibroblast cell types. This
defect is not permanent, as the removal of the antibody
produces virions capable of infecting epithelial cells. The
reversal of this defect, and the lack of a requirement for a genetic
change, suggests that in vivo the virus would be able to replicate
in a reservoir of cells that do not require the gH/gL/UL128/
UL130/UL131a complex for infection even in the presence of
the antibody. Thismechanismof antibody escape offers perhaps
the best explanation for the inability of MSL-109 to block CMV
disease progression, and when considering the dose depen-
dence of the escape mechanism in the context of MSL-109-
treated patients, it is tempting to speculate that the high doses
administered in these studies may have further enhanced the
resistance phenotype.
The binding data confirming that gH/gL-containing complexes
are the target for MSL-109 demonstrate that it binds to these
complexes when they are associated with the cell but not the
‘‘resting’’ virion. The lack of binding to cell-free virions indicates
that MSL-109 acts at a postattachment step, requiring the virus
to interact with the cell before the antibody can bind to its
epitope. This implies that the epitope for MSL-109 is either pro-
tected in the virion and is only revealed upon binding to the cell,
or that gH/gL complexes undergo conformational changes upon
binding to the cell which generate the MSL-109 epitope. This is
not uncommon, as other neutralizing antibodies have been
found to bind epitopes only exposed during virus entry (Cope-
land et al., 1986). Further study is required to truly establish thesevier Inc.
Cell Host & Microbe
Nongenetic Escape of a CMV Neutralizing AntibodyMSL-109 epitope and the mechanism of neutralization, which
will provide useful information about the role of gH/gL complexes
in CMV entry.
Our data show that while there is little cost to growth of the
resistant virus in fibroblasts, there is a restriction of virus tropism.
The loss of tropism likely stems from a defect in the gH/gL/
UL128/UL130/UL131a complex, which is known to be required
for entry into nonfibroblast cell types. The sequencing data
indicate that mutations begin to accumulate in UL131a during
MSL-109 selection in fibroblasts, which may explain the loss of
tropism, but this is not the case for all of the resistant clones,
as somewere homogenouslywild-type and still showed a restric-
tion in tropism. The reduction in UL128 protein in VR1814-
MSL109R virions (Figure 3G) indicates that the binding of
MSL-109 to gH/gL complexes may disrupt the proper formation
of the gH/gL/UL128/UL130/UL131a complex. This may offer
a better explanation for the loss of tropism and explain the ability
of the virus to regain its epithelial cell tropism following reversion.
Our data show that the mechanism of resistance to MSL-109
is not a genetic one. This stems from whole genome sequencing
in which we were unable to identify any genetic changes which
tracked with the resistance phenotype. In addition, the rapid
generation and reversion of resistance within a single passage
support the conclusion that resistance is not due to a permanent
genetic change. Sequencing data did identify accumulating
mutations in UL119, but there are multiple reasons to eliminate
this as the cause of MSL-109 resistance: first, plaque purification
of resistant virus clones should eliminate any heterogeneity in the
population with regards to a mutation that confers resistance,
but this was not the case for the resistant clones; second, there
were no corrective mutations in UL119 following reversion of the
resistance phenotype; and third, the ability of F(ab0)2 fragments
to neutralize infection (Figure S2) confirms that the gH/gL-target-
ing CDR region of MSL-109 is responsible for its neutralizing
capabilities and that UL119 has no role in the mechanism of
neutralization.
While UL119 is not the cause of resistance, the mutation of
UL119 may be the result of the resistance phenotype. UL119
and UL118 are virally encoded Fc receptors that are expressed
on both the surface of infected cells and in the virion, but both
are dispensable for growth in vitro (Atalay et al., 2002; Sprague
et al., 2008). It is thought that their function in the virion is to
protect it from immune cell recognition by binding to the Fc
domain of antibodies bound to the virion. Our data implicate
the Fc domain of MSL-109 in facilitating MSL-109-resistant virus
infection of naive cells (Figure 6), so the presence of Fc binding
receptors in the virion would be detrimental to the fitness of
the resistant virus. The accumulation of mutations in UL119
that eliminate it from the virion supports this hypothesis and
lends weight to the argument that the Fc domain of MSL-109
is important for the generation of MSL-109 resistance. Although
it should be noted that UL118 did not show any mutations in the
resistant virus, so further examination of the relationship
between UL119, UL118, and MSL-109 resistance is required to
establish why UL119 is mutated but UL118 is not.
Our data support a model in which the Fc domain of virus-
attached MSL-109 is aiding in the entry of the virus into naive
cells. The precise mechanism of how resistant virus enters cells
and the role the Fc domain plays in mediating this processCell Host & Mremain unclear. Currently our lab is attempting to generate
F(ab0)2-resistant virus. Following three passages of virus growth
in the presence of 20 times the IC50 value forMSL-109 F(ab
0)2, no
resistance has been observed (data not shown). The difficulties
in generating resistance to F(ab0)2 also argue that the Fc domain
of MSL-109 has a role to play in the generation of resistance.
However, it should be noted that the role of the Fc domain
may be 2-fold—first, in the uptake of the antibody into infected
cells to generate resistance, and second, the subsequent infec-
tion of naive cells by resistant virus. Further experimentation is
needed to fully understand how the antibody is being taken up
into cells to generate resistance, how the resistant virus is being
taken up into naive cells, and what role the Fc domain of the
antibody is playing in either of these processes.
Although there is a role for the Fc domain of the antibody in
mediating new rounds of infection into naive nonimmune cells,
the cellular factors engaged by this IgG-containing resistant
virus remain unknown. Other viruses, but not CMV, have previ-
ously been shown to utilize the Fc domain of bound antibodies
to aid uptake into cells (Halstead et al., 1984). However, there
are key differences between antibody-dependent enhancement
(ADE) and what occurs with MSL-109-resistant CMV. First,
ADE-based mechanisms described to date are defined by the
ability of nonneutralizing antibodies to mediate entry. This is
not the case for MSL-109-resistant virus, as MSL-109 is capable
of neutralizing parental VR1814. Second, in classic ADE-based
entry it is the antibody itself that is responsible for the uptake
of the virus into immune cells by binding to Fc-g receptors.
VR1814-MSL109R does not infect immune cells, such as differ-
entiated THP-1 cells, which express high levels of Fc-g receptors
(Figure S3). Third, of the known Fc receptors, NN-NHDF cells
only express the neonatal Fc receptor (FcRn). The FcRn is not
found on the surface of human cells and is therefore unlikely to
be involved in the uptake of the virus into the cell. Previously pub-
lished data have suggested that CMVmay utilize nonneutralizing
and low avidity neutralizing antibodies to bind the FcRn and
direct the virus across cell monolayers (Maidji et al., 2006). Our
data describing MSL-109 uptake into cells and binding to virions
suggest that this mechanism may also occur for potently block-
ing antibodies. Thus, antibody-mediated resistance and transcy-
tosis may be an epitope-driven effect rather than an affinity-
driven process. Further study is required to determine the exact
role of Fc-mediated uptake by the resistant virus and to deter-
mine how common this nongenetic resistance mechanism is
among naturally elicited CMV-neutralizing antibodies.
Antibody-based therapies represent a safe addition to the
current therapy for CMV disease and provide a potentially prom-
ising avenue for treating CMV disease in the congenital setting.
However, the failure of MSL-109 in clinical trials called this into
question. The implications of our findings for the generation of
an antibody therapy for CMV are significant. These data offer
a promising explanation as to why MSL-109 did not work in
the clinic by showing that CMV can utilize a nonconventional
mechanism of antibody escape. However, while this offers the
best explanation for MSL-109’s ineffectiveness, other explana-
tions, such as antibody exposure in immune privileged sites
like the eye, cannot be excluded. If CMV antibodies are to be
developed as a therapy for CMV disease, the question remains
about howcommon thismechanism of resistance is andwhethericrobe 10, 197–209, September 15, 2011 ª2011 Elsevier Inc. 207
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lab has tried to address this question by generating escape
viruses to other potently neutralizing antibodies, including to
other gH antibodies, and found that the generation of resistance
is significantly slower in comparison to the generation of resis-
tance to MSL-109, indicating that this mechanism of escape is
not a common one (Table S3). These data would suggest that
antibodies targeting other epitopes may prove more successful
at offering the high barrier of resistance that is seen with current
therapy. What is apparent is the importance of establishing the
exact mechanism of antibody neutralization and escape before
further development of a neutralizing antibody as a therapy for
CMV disease.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, Viruses, and Other Reagents
NN-NHDF, HFFs, and ARPE-19 cells were grown according to ATCC guide-
lines. HUVECs were grown in endothelial basal media (EBM) supplemented
with the EGM-2 bullet kit (LONZA). MSL-109, ITC88, 13H11, and 3G16 are
human monoclonal IgGs and have all been previously described (Macagno
et al., 2009; Nokta et al., 1994; Ohlin et al., 1993). Primary antibodies used
include IE1/2 (6F8.2) (Chemicon), gB (1.B.223) (US Biologicals), gB (2F12)
(Abcam), pp65 (Chemicon), gH (1.B.224) (Abcam), and DDR1 (C-20) (Santa
Cruz Biotechnology). gH, gL, UL130, and UL131a polyclonal rabbit antibodies
were used for immunoblotting (Kinzler et al., 2002; Ryckman et al., 2008). A
polyclonal rabbit antibody to UL128 was generated by New England Peptides
against a KLH-conjugated peptide (CNYNPLYLEADGR). Secondary anti-
bodies included horseradish peroxidase (HRP)-conjugated antibodies against
mouse IgG (Millipore), rabbit IgG (Santa Cruz Biotechnology), and human IgG
(Jackson ImmunoResearch Laboratories Inc.), and an anti-mouse AP-conju-
gated secondary (SouthernBiotech). Alexa Fluor-conjugated secondary anti-
bodieswere purchased from Invitrogen. VR1814waspropagatedas previously
described (Nowlin et al., 1991). VR1814-MSL109R and VR1814-ITC88R were
propagated in the presence of 6.6 mg/ml and 10 mg/ml of their respective anti-
bodies. Polyethylene glycol (PEG), ammonium chloride (NH4Cl), chloroquine,
chlorpromazine, and nystatin were purchased from Fisher Scientific. Protein
A and normal human IgG were obtained from Invitrogen. Soluble gH/gL/
UL128/UL130/UL131a complex was generated by Redbiotec.
FACS Analysis
Cells were detached using cell dissociation buffer (Invitrogen) and washed in
13PBS (0.137M NaCl, 0.0027M KCl, 0.1M, Na2HPO4, 0.002M KH2PO4
[pH7.4]). The cells were resuspended in 13PBS containing 2% FBS and incu-
bated with primary antibodies (1:500 in 13PBS containing 2% FBS). The cells
were washed three times in 13PBS and incubated in anti-human Alexa Fluor
647-conjugated secondary antibody (1:1000). The cells were washed three
times in 13PBS and resuspended in 150 ml of 13PBS with propidium iodide
(Invitrogen). Florescence was measured using a BD Biosciences LSRII Cell
Analyzer.
Immunoprecipitation
NN-NHDF cells were infected with adenovirus particles expressing VR1814
glycoproteins (20 PFUs/cell). Protein expression was allowed to proceed for
72 hr before the cells were washed in 13PBS and lysed in 1% NP-40. Protein
(500 mg) was incubated with 5 mg of antibody for 16 hr at 4C. Alternatively,
equivalent numbers of virions were semipurified through a 20% sorbitol
cushion before being lysed as described above. Complexes were immunopre-
cipitated using the Classic IP Kit (Pierce Biotechnology) according to the
manufacturer’s protocol. The complexes were washed four times in lysis
buffer. Samples were boiled for 5 min at 100C before immunoblotting.
ELISA Assays
Soluble gB or gH/gL/UL128/UL130/UL131a complexes were diluted in
13PBS to a concentration of 5 mg/ml. VR1814 was partially purified through
a 20% sorbitol cushion and resuspended in 13PBS. Fifty microliters of either208 Cell Host & Microbe 10, 197–209, September 15, 2011 ª2011 Elsoluble protein or diluted virus was added to each well of a MaxiSorp 96-well
flat-bottomed plate (Nunc) and allowed to absorb overnight at 4C. Unbound
protein was removed and the plate washed three times with 13PBST. Plates
were blocked in 13PBS with 5% milk (Bio-Rad) for 2 hr. Serial dilutions of the
antibodies were made in 13PBS containing 1% BSA (Fisher Scientific).
Primary antibody (50 ml/well) was incubated at room temperature for 1 hr.
The plate was washed three times with 13PBST, and primary antibody was
detected using a 1:5000 dilution of anti-human HRP-conjugated antibody for
1 hr at room temperature. The plate was washed three times with 13PBST,
and signal was detected with SureBlue TMB substrate (KPL). Plates were
read at 650 nm by a Spectramax 340PC plate reader.
Immunofluorescense
For confocal microscopy, cells were grown on tissue culture-treated chamber
slides (BDFalcon) andfixed in 4%paraformaldehyde.Cellswerepermeabilized
in 0.1% Triton X and incubated with mouse anti-gH antibody (1:500) for 2 hr.
Cells were washed three times in 13PBS and incubated with anti-mouse
AF546 (1:2000), anti-human AF488 (1:1000), and DAPI (1:5000) for 1 hr. The
slides were washed three times in 13PBS andmounted with coverslips (Fisher
Scientific) usingfluorsave (Calbiochem).AZeissLSM510ConfocalMicroscope
was used for imaging. For antibody neutralization assays, 12,000 cells per well
wereplated in 96-well platesand infectedwith virus that hadbeenpreincubated
withantibody.Twenty-fourhoursp.i., cellswerestainedasaboveusingamouse
anti-IE antibody (1:2000) and an anti-mouse Alexa Fluor 594 secondary
antibody (1:3000). The number of IE-positive cellswas counted usingCellomics
Arrayscan. The IC50 values of the antibodies were generated using XLfit.
Plaque Assay
23 105NN-NHDF cells were plated per well of a 24-well dish. Virus was diluted
to 102 in serum-freemedia, and 10-fold dilutions weremade out to 107. Cells
were washed three times in serum-free media before virus was added. Three
hours p.i. the media was removed and cells were overlaid with 1.5 ml of a 1:1
mix of 23DMEM and 1.2% agarose. An additional 1.5 ml of 13DMEM was
added to each well. The VR1814-MSL109R virus was maintained in 6.6 mg/ml
of MSL-109. The cells were left for 14 days at 37C in 5% CO2. Cells were
washed and fixed for 10 min in 100% methanol at room temperature. Cells
were permeabilized for 10 min in 13PBS containing 0.5% Triton X and stained
for gB using an anti-CMV gB antibody (US Biologicals) at 1:500 for 1 hr. Signal
was detected using a goat anti-mouse AP-conjugated secondary (Southern-
Biotech) and BCIP/NBT solution (KPL Research).
Genome Sequencing
Genomic DNA was fragmented using a Covaris S2 sonication device
(K-Biosciences). DNA was subjected to end repair and linker ligation as per
the SOLiD 3+ recommended procedure (Applied Biosystems). The library
was size selected, and molecular barcodes were added to each sample (Life
Technologies, Foster City). The libraries were quantitatively pooled and
6 pmoles attached to magnetic beads (Life Technologies, Foster City). Emul-
sion PCR, bead enrichment, purification, and slide deposition were performed
as recommended (Life Technologies). The beads were checked for polyclon-
ality using a standard WFA run on the SOLiD3+ system. The production flow
cell was deposited and samples subjected to 50 bases of ligation-mediated
sequencing on the SOLiD3+ system.
Sequences were aligned to the reference (GU179289.1) using the BFAST
algorithm as follows: SOLiD CSFASTA files and QUAL files were converted
to FASTQ format using the BFAST utility program ‘‘solid2fastq.’’ Ten BFAST
reference genome indices were built using the recommended masks. The
BFAST match, localalign, and postprocess routines were run. Reads with
a unique best-scoring alignment were output in SAM format. The GATK (The
Genome Analysis Toolkit) package was used to call SNPs and INDELs (Homer
et al., 2009a, 2009b). The SAM files from BFAST were recalibrated as recom-
mended. Local realignment was run on candidate sites detected by the soft-
ware. SNPs and INDELs were called separately by ‘‘UnifiedGenotyper’’ and
‘‘IndelGenotyperV2.’’
Quantitative Real-Time PCR
Cells were infected for 3 days before total RNA or DNA were harvested using
the QIAGEN RNeasy mini kit or the QIAGEN Blood DNA extraction kit. RNAsevier Inc.
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Biosystems). DNA copy numberwas detected using TaqmanGene Expression
Master Mix and a 7900HT Fast Real-Time PCR system (Applied Biosystems).
Primers and probes for each target gene were designed using Primer Express
software (Applied Biosystems) against conserved regions (Supplemental
Experimental Procedures). The probes were labeled at the 50 end with 6-car-
boxyfluorescein (FAM) and at the 30 end with 6-carboxytetramethylrhodamine
(TAMRA) (Integrated DNA Technologies).SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.chom.2011.07.010.
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